Renew your interest in ED or lose it to other specialists
Primary care specialties now account for more than 75% of the prescriptionswritten for sildenafil citrate (Viagra), and this percentage increases almostmonthly. The number of prescriptions written by urologists has remainedstable, and as the erectile dysfunction market increases, urology's percentageof the whole continues to decline. As a specialty, urologists are very busy, and the ratio of patients tophysicians is high. Urology residents who are finishing training have atremendous number of practice opportunities, ranking second only to residentsin dermatology, according to a recent AMA survey. Just look at the numberof classified pages in this issue of Urology Times, which list some of theseopportunities, and compare it with those in an issue of 5 or 10 years ago.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.